CA
ATOS icon

Cetera Advisors’s Atossa Therapeutics ATOS Stock Holding History

Cetera Advisors’s Portfolio ATOS Stock Details ATOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		$71.8K Buy
+2,660
New +$42.7K ﹤0.01% 2334

Other funds holding ATOS

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return

Cetera Advisors's ATOS Position: Q1 2024 in Review

Cetera Advisors opened a new position in Atossa Therapeutics (ATOS) in Q1 2024: 2,660 shares worth $71.8K. The stake represents ﹤0.01% of the portfolio and ranks #2334 among its holdings.

67 funds tracked by Wall St. Rank hold ATOS as of Q1 2024.

  • Cetera Advisors held 2,660 shares of Atossa Therapeutics worth $71.8K as of Q1 2024.
  • Atossa Therapeutics was a new Cetera Advisors position in Q1 2024.
  • Atossa Therapeutics made up ﹤0.01% of Cetera Advisors's portfolio in Q1 2024, its #2334 holding.
  • 67 funds tracked by Wall St. Rank held Atossa Therapeutics as of Q1 2024.

Based on Cetera Advisors's 13F filing for Q1 2024, filed 15 May 2024.